Literature DB >> 13304674

Anemia in patients with neoplastic diseases.

A J SAMUELS, H R BIERMAN.   

Abstract

A specific and characteristic type of anemia is not a feature of all malignant disease. To the contrary, the nature of the anemia will depend upon the causative mechanism, of which blood loss and accelerated erythrocyte removal appear to be the most frequently seen and the most clearly defined. Recognition of anemia due to loss of blood is relatively simple if the subtlety of blood loss in the stool is borne in mind and persistent testing to demonstrate it is carried out. Indeed, anemia characterized by chronic loss of blood in men can only mean chronic gastrointestinal bleeding if certain rare hemoglobin abnormalities can be ruled out. Anemia due to accelerated erythrocyte removal may also be recognized by simple measures. After transfusions raise hemoglobin values to near normal levels, the disappearance of the transfused blood and the rapid return of the pretransfusion severity of anemia are good evidence of the presence of such a mechanism, if blood loss can be ruled out.Adequate management of the anemia of malignant disease depends upon a clear understanding of the various mechanisms involved. It is highly probable that attention to this feature will, in many instances, significantly prolong the productive life of persons with malignant disease.

Entities:  

Keywords:  ANEMIA; NEOPLASMS/blood in

Mesh:

Year:  1956        PMID: 13304674      PMCID: PMC1532925     

Source DB:  PubMed          Journal:  Calif Med        ISSN: 0008-1264


  3 in total

1.  Studies on anemia of disseminated malignant neoplastic disease. I. The hemolytic factor.

Authors:  G A HYMAN
Journal:  Blood       Date:  1954-09       Impact factor: 22.113

2.  Radioactive sodium chromate for the study of survival of red blood cells. II. The rate of hemolysis in certain hematologic disorders.

Authors:  I M WEINSTEIN; G V LEROY
Journal:  J Lab Clin Med       Date:  1953-09

3.  A study of blood volume and anemia in cancer patients.

Authors:  J C BATEMAN
Journal:  Blood       Date:  1951-07       Impact factor: 22.113

  3 in total
  3 in total

1.  Sideropenic anaemia with reticulo-endothelial siderosis in a case of hypernephroma.

Authors:  K Chatterjee; G E MacLellan
Journal:  Postgrad Med J       Date:  1968-03       Impact factor: 2.401

2.  Anaemia in the reticuloses.

Authors:  A J BOWDLER; T A PRANKERD
Journal:  Br Med J       Date:  1962-04-28

3.  Effect of subcutaneous recombinant human erythropoietin in cancer patients receiving radiotherapy: final report of a randomized, open-labelled, phase II trial.

Authors:  P J Sweeney; D Nicolae; L Ignacio; L Chen; M Roach; W Wara; K C Marcus; S Vijayakumar
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.